Edwards Lifesciences Corporation (NYSE:EW) Receives Average Rating of “Moderate Buy” from Analysts

Edwards Lifesciences Corporation (NYSE:EW) has been given an average rating of “Moderate Buy” by the twenty-nine analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating, sixteen have given a buy rating and three have issued a strong buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $96.4545.

A number of analysts have recently issued reports on EW shares. Barclays reaffirmed an “overweight” rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Citigroup restated a “buy” rating and issued a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $108.00 price target on shares of Edwards Lifesciences in a research note on Friday, January 9th.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 57,824 shares of company stock valued at $4,863,323 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Level Four Advisory Services LLC boosted its stake in Edwards Lifesciences by 3.7% during the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after buying an additional 119 shares during the period. Colonial Trust Co SC boosted its position in shares of Edwards Lifesciences by 0.4% during the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after purchasing an additional 120 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Edwards Lifesciences by 9.8% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after purchasing an additional 130 shares during the period. Prosperity Consulting Group LLC increased its holdings in Edwards Lifesciences by 3.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after purchasing an additional 132 shares during the last quarter. Finally, Howard Capital Management Inc. raised its position in Edwards Lifesciences by 3.3% in the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after purchasing an additional 132 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.1%

EW stock opened at $84.39 on Monday. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a 50-day simple moving average of $85.12 and a 200-day simple moving average of $80.59. The stock has a market capitalization of $48.97 billion, a P/E ratio of 36.38, a P/E/G ratio of 3.39 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company posted $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.